U.S. Household Products Stock News

Horizon Bancorp (HBNC) recently expanded its Board of Directors from 11 to 13 members, adding Nicholas J. Ritter and Charles W. Sulerzyski to the Class of 2027 and to the Horizon Bank board. See our latest analysis for Horizon Bancorp. At a share price of $20.28, Horizon Bancorp has seen modest short term share price softness, while its 90 day share price return of 10.64% and 1 year total shareholder return of 31.20% point to stronger underlying momentum. If this board refresh has you...

Right now, tariffs and trade rules are reshaping the economics of polysilicon and solar grade silicon, turning supply chains into a live stress test for listed stocks. That disruption can create pricing power for some companies and fresh risks for others, which is why investors are watching this corner of the market so closely. This article walks through three screened stocks that appear particularly exposed to the latest policy shock. The three stocks highlighted below are just a starting...

BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this month. See our latest analysis for BeOne Medicines. Following the earnings beat and raised 2026 guidance, BeOne Medicines stock has picked up momentum, with an 18.31% 1 month share price return and a 19.57% 3 month share price return. That sits alongside an 18.12% 1 year total shareholder return...

La-Z-Boy (LZB) is back in focus after reporting first quarter results for the period ended July 25, 2026, showing sales of US$475.69 million and a net loss of US$2.29 million. See our latest analysis for La-Z-Boy. The earnings miss and quarterly net loss have taken some heat out of La-Z-Boy’s recent gains, with the share price down 1.7% over the past week but still up 14.9% over 90 days and a 3 year total shareholder return of 46.7%. This suggests longer term holders have seen stronger...

Why Roivant Sciences Earnings Matter For Shareholders Roivant Sciences (ROIV) reported first quarter 2026 results with sales of US$1.44 million compared to US$2.17 million a year earlier, while the net loss narrowed to US$189.84 million from US$223.36 million. See our latest analysis for Roivant Sciences. Roivant Sciences shares have gained momentum around the earnings release, with a 1-month share price return of 8.29% and a year to date share price return of 70.41%. The 1-year total...

CNB Financial (CCNE) drew fresh attention after its Board declared a quarterly cash dividend of $0.19 per share, payable on September 15, 2026, to shareholders of record on September 1, 2026. See our latest analysis for CNB Financial. At a share price of US$34.82, CNB Financial has seen its short term momentum build, with a 90 day share price return of 14.09% and a year to date share price return of 35.28%. The 1 year total shareholder return of 43.63% and 3 year total shareholder return of...

Why Trulieve Cannabis Stock Is Back In Focus After Its NYSE Debut Trulieve Cannabis (TRLV) drew fresh attention after ringing the New York Stock Exchange Closing Bell and becoming the first U.S. cannabis company to list on the NYSE. The move signals higher visibility and potentially wider investor access. The NYSE listing sits alongside Trulieve Cannabis operations that include 207 medical dispensaries, 5,000 employees, and 3.5 million square feet of cultivation and production capacity across...

In August 2026, Amylyx Pharmaceuticals reported positive topline Phase 3 LUCIDITY results showing avexitide significantly reduced serious hypoglycemic events in post-bariatric hypoglycemia after Roux-en-Y gastric bypass, while also launching a US$350,000,000 follow-on common stock offering and outlining plans to submit a New Drug Application by late 2026. This marks progress for a first-in-class GLP-1 receptor antagonist in a condition with no FDA-approved therapies, potentially opening a...

Sea stock is coming off a sharp three year gain of 218.3% but the valuation signals are split, with the Discounted Cash Flow (DCF) intrinsic value pointing to upside while market based multiples lean the other way. That mix leaves investors weighing a strong share price recovery against a set of checks that only partly support the current level. Sea has returned 218.3% over the last three years, which puts the focus on whether that rebound already reflects most of the good news. The recent...

Why MannKind's latest earnings matter for shareholders MannKind (MNKD) recently reported second quarter 2026 results that combined higher revenue with a shift back to losses. This mix of topline expansion and weaker profitability is now central to how investors assess the stock. See our latest analysis for MannKind. MannKind's recent earnings release has arrived after a period where the stock has swung between pressure and recovery, with a 25.23% 90 day share price return against a weaker...

Shelf registration puts funding options on the table National Fuel Gas (NFG) has filed an omnibus shelf registration covering debt, common and preferred stock, depositary shares, stock purchase contracts and units. This filing refreshes the company’s ability to raise capital through multiple security types. See our latest analysis for National Fuel Gas. At a share price of US$83.37, National Fuel Gas has seen a 1-day share price return of 1.89% and a 30-day share price return of 3.00%. The...

Tango Therapeutics, Inc. recently reported a wider net loss of US$55.34 million for the second quarter of 2026, filed a US$400 million at-the-market follow-on equity offering, and made several leadership changes including appointing a new Chairman and a future Chief Commercialization Officer. These moves point to a company aligning its capital-raising plans with the build-out of commercialization expertise as it prepares vopimetostat for later-stage development. Next, we will examine how the...

What Viridian Therapeutics’ Latest Earnings Mean For Investors Viridian Therapeutics (VRDN) reported its second quarter and six month results to June 30, 2026, giving investors fresh detail on revenue and losses that appear to be driving recent stock interest. Quarterly revenue was US$0.284 million compared with US$0.075 million a year earlier. Net loss for the period was US$127.12 million, with basic loss per share from continuing operations at US$1.05 compared with US$1 in the prior year...

In August 2026, MDU Resources Group’s board raised its quarterly dividend to US$0.145 per share, updated its long‑term dividend payout ratio target to 55%–65% of earnings, and set an October 1, 2026 payment date for shareholders of record on September 10, 2026. This combination of a higher cash payout and a lower target payout range highlights management’s focus on balancing income returns with earnings retention for future investment. Next, we’ll examine how the dividend increase and...

Missile launches toward the UAE, fresh trade restrictions with Iran and renewed threats to shipping near the Strait of Hormuz have pushed Middle East risk back onto investors’ screens in 2026. These shocks can reshape pricing for energy and defense stocks linked to the region, which creates both potential openings and hazards for a diversified portfolio. This article walks through 3 stocks from our screener that appear positively exposed to this backdrop. The three stocks below are just a...

Recently, Prosperity Bancshares was highlighted for offering a 3.2% dividend yield, above both its banking peers and the S&P 500, with five years of consistent dividend increases supported by a payout ratio of about 40% of earnings. An interesting angle for investors is how this combination of above-average yield, measured dividend growth and a seemingly sustainable payout level is refocusing attention on Prosperity Bancshares’ income profile. We’ll now examine how Prosperity Bancshares’...

IDEX (IEX) shares were back in focus after the company disclosed that director L. Paris Watts-Stanfield resigned from its Board on August 13, 2026, prompting a reduction from ten to nine directors. See our latest analysis for IDEX. The share price of IDEX has eased in the very short term, with a 1-day share price return that declined 2.59% and a 7-day share price return that declined 1.33%. Momentum over longer periods remains positive, with a 30.77% year to date share price return and a...

Event context for CONMED and recent performance snapshot Recent commentary on CONMED (CNMD) highlights adoption of its AirSeal, Buffalo Filter, and BioBrace platforms alongside tariff and product specific growth risks. Investors are weighing this product mix against the stock’s recent share price moves. See our latest analysis for CONMED. At a share price of US$49.26, CONMED has seen its 30 day share price return of 14.03% and 90 day share price return of 33.10% contrast with a 1 year total...

Baidu (BIDU) is back in focus after its latest earnings release on August 18, 2026, which showed lower sales and net income compared with a year earlier, prompting investors to reassess the stock. See our latest analysis for Baidu. The latest earnings setback has been mirrored in Baidu's trading, with the share price at US$90.87 and recent share price returns down 12.73% over one day, 15.26% over 30 days, and 39.54% year to date, while the 1 year total shareholder return is positive at 2.02%...

Why BBB Foods Stock Is Back In Focus After Earnings And Capital Plans BBB Foods (TBBB) is drawing attention after reporting second quarter and half year results that paired higher revenue with wider net losses, followed closely by a large shelf registration for potential share issuance. See our latest analysis for BBB Foods. The recent earnings update and US$1.53b shelf registration appear to have sharpened focus on BBB Foods, with the share price at US$48.06 after a 7 day share price return...

Long term Treasury yields near multi decade highs are reshaping where credit risk feels most exposed. AI and tech stocks tied to heavy spending are being repriced as debt, not just growth stories, which is pulling attention toward listed private credit and alternative lenders. This article walks through three stocks from that universe that appear well positioned relative to these shocks and explains how their exposure to the news could matter for your portfolio. The three listed private...

DXP Enterprises reported past second-quarter 2026 results showing sales of US$576.46 million and net income of US$28.71 million, with both basic and diluted earnings per share from continuing operations higher than a year earlier. Over the first half of 2026, DXP’s higher sales and earnings, alongside prior commentary about strong long-term revenue and earnings-per-share expansion, highlight how its growth initiatives are translating into improved profitability. With this earnings strength...

In August 2026, Oruka Therapeutics, Inc. reported second-quarter and six-month results showing net losses of US$41.21 million and US$73.03 million, respectively, with basic loss per share from continuing operations rising to US$0.55 for the quarter and US$1.04 for the half year compared with the prior period. The results highlight that Oruka’s losses and loss per share have increased compared with a year earlier, sharpening investor focus on how the company is funding and pacing its...

AtaiBeckley (ATAI) drew fresh attention after releasing second quarter 2026 results, reporting revenue of US$1.7 million and a net loss of US$32.52 million, while loss per share from continuing operations improved year over year. See our latest analysis for AtaiBeckley. AtaiBeckley’s recent earnings release comes after a sharp shift in sentiment, with a 90 day share price return of 78.24% and a 3 year total shareholder return above 300%, although the 5 year total shareholder return remains...